Prot# CA182006: A Phase II Open Label Study of Brivanib (BMS-582664), Administered Orally At A Dose of 800 Mg Daily In Subjects with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy o

Project: Research project

Project Details

Effective start/end date6/27/074/1/12


  • Bristol-Myers Squibb Company (CA182006)